Anti-citrullinated peptide antibodies (ACPA) are an important feature of rheumatoid arthritis (RA), and the presence of these autoantibodies is associated with a more-erosive disease course. In this Review, the authors provide an overview of the discovery and development of ACPA as a biomarker in RA, and discuss the future research directions that might further enhance its clinical utility.
- Walther J. van Venrooij
- Joyce J. B. C. van Beers
- Ger J. M. Pruijn
